Asia Pacific Biologics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 141,276.35 |
 CAGR |
% |
| Major Markets Players |
Asia-Pacific Biologics Market, By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution) Industry Trends and Forecast to 2030.
Asia-Pacific Biologics Market Analysis and Insights
Biologics are the drugs produced from living organisms or some components of living organisms. These drugs can be derived from different biological sources, including humans, avian cell culture, yeast, bacteria, and insect cell culture among others. These drugs involve therapeutic proteins, monoclonal antibodies, and vaccines. These drugs can be used to treat different types of chronic conditions, including cancers, inflammatory diseases, metabolic diseases, cardiovascular diseases, and infectious diseases.
Asia-Pacific biologics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyzes that the market is growing with a CAGR of 11.5% in the forecast period of 2023 to 2030 and is expected to reach USD 141,276.35 million by 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable to 2020-2016) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), and Others), Type (Monoclonal Antibodies (MABs), Therapeutic Proteins, Vaccines, Cellular Based Biologics, Gene Based Biologics, and Others), Route of Administration (Injection and Infusion), Application (Oncology, Autoimmune Diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, and Others), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insects Cell Culture, Transgenics, and Others), End User (Hospitals, Specialty Clinics, Academics and Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Third Party Distribution). |
|
Countries Covered |
China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, and rest of Asia-Pacific. |
|
Market Players Covered |
AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others. |
Market Definition
Biologics are the drugs produced from living organisms or some components of living organisms that have several advantages compared to other drug types, including small molecules. These are very much target-specific which has enhanced the demand among healthcare professionals. Moreover, the side effects caused are mostly related to exaggerated pharmacological effects, leading to mild health effects. Biologic drugs have also been proven to hold high potential for several therapeutic areas and have revolutionized treatments of several serious illnesses. For instance, Rituximab (chimeric monoclonal antibody) has significantly improved non-Hodkings lymphoma.
The major factor that drives the market growth is the rise in the prevalence of chronic diseases such as diabetes and cancer in developing countries. Furthermore, rise in initiatives by governments and surge in research for new biologics drugs are some of the factors that boost the market growth. However, lack of awareness about healthcare in developing countries is a major factor that restrains the market growth. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for market expansion in the forecast period.
Asia-Pacific Biologics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
- Rising prevalence of chronic diseases such as diabetes and cancers
Chronic diseases are one of the biggest healthcare concerns in the world, claiming an estimated 40 million lives every year, 8.5 million of whom reside in Asia. In Asia-Pacific, cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions are among the most common chronic diseases. This is primarily driven by aging populations and poor lifestyle choices such as the lack of physical activity and tobacco & alcohol consumption.
- Changes in lifestyle
Lifestyle diseases share risk factors similar to prolonged exposure to three modifiable lifestyle behaviors, smoking, unhealthy diet, and physical inactivity, and result in the development of chronic diseases, specifically heart disease, stroke, diabetes, obesity, metabolic syndrome, Chronic Obstructive Pulmonary Disease (COPD), and some types of cancer.
- Recent advancements in biologics
Delivery by injection is the most convenient method for biologics delivery. It is not always ideal. This is primarily because of the pharmacokinetics of biologics, which means they are rapidly cleared from systemic circulation.
Co-formulation of therapeutics is an emerging strategy that aims to capitalize on advances in therapeutic effects observed through the co-administration of biologics.
RESTRAINTS
- Complex manufacturing process of biologics
Biologics drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as Critical Quality Attributes (CQAs), can vary based on post-translational modifications that occur in the cellular environment or during the manufacturing process. The complexity of the manufacturing process leads to several defaults. Thus, the complex manufacturing process of biologics is acting as a major restraining factor for market growth.
- Adverse side-effects of biologics
Like standard pharmaceuticals, biological treatments can cause adverse drug reactions. They can cause allergic reactions similar to the ways these drugs can. But they can also cause problems due to the way biologics interact with the immune system. They can also sometimes cause specific issues with various organ systems in the body.
Some of the side effects associated with biologics are:
- Injection site reactions
- Infusion reactions
Usually, these reactions are mild. However, sometimes they may be more severe such as hypersensitivity reactions, and require medical intervention.
Thus, adverse side effects of biologics treatment act as a restraint for market growth.
OPPORTUNITIES
- Rising healthcare expenditure
Across the globe, R&D activities are escalating owing to public health expenditure with economic performance. At the same time, the healthcare industry ranks second among all industries regarding R&D. Rising healthcare expenditure can result in better provision of R&D opportunities. That results in the anticipated upsurging demand for various cancer diagnostics.
- Strategic initiatives by market players
An increase in the burden of various types of diseases such as cancers, diabetes, and cardiovascular diseases across Asia-Pacific, coupled with the rise in the geriatric population, has created more demand for biologics. The main aim is to improve health management in biologics for quality care with convenient application. Hence, major market players are focusing on fulfilling the demand for biologics and spending a noticeable amount on better products.
Thus, these strategic product launches, acquisitions, and mergers by major companies in the biologics market have opened up opportunities for companies in Asia. This strategy is allowing the companies to strengthen their footprints in the market.
- Surge in healthcare expenditure
Healthcare expenditure has increased across Asia-Pacific region, as the disposable income of people across Asia is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare organizations to improve their treatment facilities for the usage of biologics.
- Growing number of biopharmaceutical contract manufacturing companies in Asia
The biopharmaceutical contract manufacturing market is growing essentially due to the increasing demand for biologics and increasing outsourcing by pharmaceutical companies in Asia-Pacific. Increasing competition in the industry is likely to damage the market growth in the coming years. Additionally, robust advancements in R&D activities, emerging markets, and consolidation in the pharmaceutical CMO industry are likely to increase the growth of biopharmaceutical contract manufacturing companies during the forecast period.
The growing number of biopharmaceutical contract manufacturing companies leads to the development of new products via rigorous research to treat various diseases. Thus, this acts as an opportunity for market growth.
CHALLENGE
- Stringent regulatory policies
Regulation of drugs plays a significant role in healthcare. Achieving the requisite approval for the legal selling of medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or taken into account, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins among others are of significant importance for treating various diseases. But their approval and marketing in multiple regions across Asia require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.
Thus, the above-mentioned stringent regulations and policies for approving the complicated nature of biologics act as a challenge to market growth.
Post-COVID-19 Impact on Asia-Pacific Biologics Market
The COVID-19 pandemic had somewhat negative impact on the biologics market. Due to the pandemic, new norms and regulations were imposed, such as social distancing and lockdown to prevent the spread of virus. As a result, people all over the world were forced to stay at home. This stay-at-home led to a decrease in the consumption of biologics, which further led to a decrease in the demand for biologics.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the quality of biologics existing in the market.
Recent Developments
Many product launches and agreements are also initiated by companies worldwide which are accelerating the market growth.
- In November 2021, Biocon launched Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in collaboration with Viatris Inc. The new product launch helped patients control high blood sugar in adults and pediatric patients suffering from diabetes 1 and diabetes 2.
- In December 2019, Bharat Biotech launched ROTAVAC 5D-lowest dose volume rotavirus vaccine across the world. The product launch was developed in partnership with the Department of Biotechnology, Government of India.
Asia-Pacific Biologics Market Scope
Asia-Pacific biologics market is segmented into seven notable segments based on class, type, route of administration, application, source material, end user, and distribution channel.
By Class
- Tumor Necrosis Factor-Α (TNF) Inhibitors
- B-Cell Inhibitors
- Interleukin Inhibitors
- Selective Co-Stimulation Modulators (Abatacept)
- Others
Based on class, the market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others.
By Type
- Monoclonal Antibodies (mABs)
- Therapeutic Proteins
- Vaccines
- Cellular Based Biologics
- Gene Based Biologics
- Other
Based on type, the market is segmented into monoclonal antibodies (mABs), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and other.
By Route of Administration
- Injection
- Infusion
Based on route of administration, the market is segmented into injection, and infusion.
By Application
- Oncology
- Autoimmune Diseases
- Diabetes
- Infectious Diseases
- Cardiovascular Diseases
- Ophthalmic Diseases
- Dermatological Diseases
- Others
Based on application, the market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others.
By Source Material
- Humans
- Avian Cell Culture
- Yeast
- Bacteria
- Insects Cell Culture
- Transgenics
- Others
Based on source material, the market is segmented into humans, avian cell culture, yeast, bacteria, insect cell culture, transgenics, and others.
By End User
- Hospital
- Specialty Clinics
- Academics and Research Institutes
- Others
Based on end user, the market is segmented into hospitals, specialty clinics, academics and research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Third Party Distribution
Based on distribution channel, the market is segmented into direct tender, retail sales, and third party distribution.
Asia-Pacific Biologics Market Regional Analysis/Insights
The Asia-Pacific biologics market is analyzed and market size information is provided based on country, class, type, route of administration, application, source material, end user, and distribution channel.
In 2022, Asia-Pacific was growing due to the rising prevalence of chronic diseases such as diabetes and cancer. China is expected to dominate the market due to recent advancements in biologics.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Biologics Market Share Analysis
Asia-Pacific biologics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus related to the market.
Some of the major players operating in this market are AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of Asia-Pacific biologics market
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- class LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- vendor share analysis
- MARKET application COVERAGE GRID
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insights
- Pestel's ANALYSIS
- Porter’s five forces
- Epidemiology
- Pipeline analysis
- Asia-Pacific Biologics Market: Laws and regulations
- market overview
- DRIVERS
- INCREASE IN PREVALENCE OF CHRONIC DISEASES SUCH AS DIABETES AND CANCERS
- CHANGES IN LIFESTYLE
- RECENT ADVANCEMENTS IN BIOLOGICS
- RESTRAINTS
- COMPLEX MANUFACTURING PROCESS OF BIOLOGICS
- ADVERSE SIDE-EFFECTS OF BIOLOGICS
- OPPORTUNITIES
- RISE IN HEALTHCARE EXPENSES
- STRATEGIC INITIATIVES BY MARKET PLAYERS
- surge in healthcare expenditure
- GROWING NUMBER OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING COMPANIES IN ASIA
- CHALLENGE
- STRINGENT REGULATORY POLICIES
- COVID-19 IMPACT ON Asia-Pacific biologics Market
- impact on price
- impact on demand
- IMPACT ON SUPPLY CHAIN
- STRATEGIC DECISIONS of Government and MANUFACTURERS
- Conclusion
- Asia-Pacific biologics market, BY class
- overview
- Tumor Necrosis Factor-Α (TNF) Inhibitors
- Adalimumab
- Certolizumab
- Etanercept
- Infliximab
- Others
- B-Cell Inhibitors
- Belimumab
- Rituximab
- others
- Interleukin Inhibitors
- Anakinra
- Canakinumab
- Ixekizumab
- Secukinumab
- Tocilizumab
- Ustekinumab
- Others
- Selective Co-Stimulation Modulators (Abatacept)
- Others
- Asia-Pacific biologics market, BY route of administration
- overview
- INjECTION
- infusion
- Asia-Pacific biologics market, BY drug classification
- overview
- Branded Drugs
- generic drugs
- Asia-Pacific biologics market, BY source material
- overview
- Bacteria
- Avian Cell Culture
- Humans Cell Lines
- Yeast
- Insects Cell Culture
- Transgenics
- asia-pacific biologics MARKET, By type
- overview
- Monoclonal Antibodies (Mabs)
- Anti-Cancer Mabs
- Immunological Mabs
- Anti-Infective Monoclonal Antibodies (Mabs)
- Cardiovascular And Cerebrovascular Mabs
- Neuropharmacological Mabs
- Others Mabs
- Therapeutic Proteins
- Metabolic Disorders Therapeutic Proteins
- Cancer Therapeutic Proteins
- Cardiovascular Therapeutic Proteins
- Immunological Therapeutic Proteins
- Others Therapeutic Proteins
- Vaccines
- Anti-Infective Vaccines
- Autoimmunity Vaccines
- others
- cellular bassed biologics
- gene based biologics
- others
- asia-pacific biologics MARKET, By application
- overview
- oncology
- Breast Cancer
- Lung Cancer
- Leukemia
- Ovarian Cancer
- Non-Hodgkin Lymphoma
- Prostate Cancer
- Colorectal Cancer
- Others
- Infectious Diseases
- Autoimmune Diseases
- Rheumatoid Arthritis
- Systemic Lupus Erythematous
- Systemic Sclerosis
- Crohn’s Disease
- Sjogren's Syndrome
- Multiple Sclerosis
- Pernicious Anemia
- Others
- Diabetes
- Cardiovascular Diseases
- Ophthalmic Conditions
- Dermatological Diseases
- others
- asia-pacific biologics MARKET, By end user
- overview
- Hospitals
- Specialty Clinics
- Others
- asia-pacific biologics MARKET, By distribution channel
- overview
- hospital pharmacies
- retail pharmacies
- online Pharmacies
- ASIA-PACIFIC biologics market, By Country
- Asia-Pacific
- China
- japan
- India
- Australia
- South Korea
- Singapore
- Malaysia
- INDONESIA
- THAILAND
- Philippines
- VIETNAM
- REST OF ASIA-PACIFIC
- Asia-Pacific Biologics market: COMPANY landscape
- company share analysis: Asia-Pacific
- swot analysis
- company profile
- F. Hoffmann-La Roche Ltd
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- pfizer Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- MERGER
- bristol-meyers squibb company
- COMPANY SNAPSHOt
- Revenue analysis
- product portfolio
- recent developments
- MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- GLAXOSMITHKLINE PLC
- COMPANY SNAPSHOt
- Revenue analysis
- product portfolio
- recent development
- abbvie Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- FDA APPROVAL:
- AGC Biologics
- COMPANY SNAPSHot
- product Portfolio
- RECENT DEVELOPMENTS
- Bharat Biotech
- COMPANY SNAPSHot
- product Portfolio
- RECENT DEVELOPMENTS
- Biocon
- COMPANY SNAPSHot
- Revenue analysis
- product Portfolio
- RECENT DEVELOPMENTs
- BioDiem
- COMPANY SNAPSHot
- Revenue analysis
- Technology Portfolio
- RECENT DEVELOPMENT
- catalent, inc.
- COMPANY SNAPSHOt
- revenue analysis
- product portfolio
- recent development
- Celltrion Healthcare Co.,Ltd.
- COMPANY SNAPSHOt
- Revenue analysis
- product portfolio
- recent development
- Johnson & Johnson Services, Inc.
- COMPANY SNAPSHOt
- revenue analysis
- product portfolio
- recent development
- Biogen
- COMPANY SNAPSHot
- Revenue analysis
- product Portfolio
- RECENT DEVELOPMENT
- BeiGene
- COMPANY SNAPSHot
- Revenue analysis
- product Portfolio
- RECENT DEVELOPMENTS
- chime biologics
- COMPANY SNAPSHOt
- SERVICE portfolio
- recent development
- Cipla Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Evotec
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ACQUISITION
- FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- COMPANY SNAPSHot
- REVENUE ANALYSIS
- product Portfolio
- RECENT DEVELOPMENT
- Innovent
- COMPANY SNAPSHot
- REVENUE ANALYSIS
- product Portfolio
- RECENT DEVELOPMENTS
- Intas Pharmaceutical Ltd.
- COMPANY SNAPSHot
- product Portfolio
- RECENT DEVELOPMENT
- Ipsen Pharma
- COMPANY SNAPSHot
- REVENUE ANALYSIS
- product Portfolio
- RECENT DEVELOPMENT
- KM Biologics (A Subsidiary of Meiji Holdings Co., Ltd.)
- COMPANY SNAPSHot
- Revenue analysis
- product Portfolio
- RECENT DEVELOPMENT
- nbhl ltd.
- COMPANY SNAPSHOt
- product portfolio
- recent development
- Panacea Biotec
- COMPANY SNAPSHot
- REVENUE ANALYSIS
- product Portfolio
- RECENT DEVELOPMENT
- Qilu Pharmaceutical Co., Ltd.
- COMPANY SNAPSHot
- product Portfolio
- RECENT DEVELOPMENT
- SAMSUNG biologics
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- ACQUISITION
- serum institute of india pvt. ltd.
- COMPANY SNAPSHOt
- product portfolio
- recent developments
- Shanghai Henlius Biotech, Inc.
- COMPANY SNAPSHot
- Revenue analysis
- product Portfolio
- RECENT DEVELOPMENTS
- Teva Pharmaceutical Industries Ltd.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- EXPANSION:
- wuxi biologics
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- LICENSE:
- YL Biologics
- COMPANY SNAPSHot
- product Portfolio
- RECENT DEVELOPMENT
- questionnaire
- related reports
List of Table
TABLE 1 pipeline analysis
TABLE 2 REGULATION imposed by several regulatory agencies in different countRIes
TABLE 3 Asia-Pacific Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 4 Asia-Pacific Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 5 Asia-Pacific B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 6 Asia-Pacific Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 7 Asia-Pacific Biologics MARKET, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 8 Asia-Pacific Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 9 Asia-Pacific biologics Market, By Source material, 2020-2029 (USD Million)
TABLE 10 Asia-Pacific biologics Market, By type , 2020-2029 (USD Million)
TABLE 11 Asia-Pacific Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 12 Asia-Pacific Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 13 Asia-Pacific Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 14 Asia-Pacific Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 15 Asia-Pacific Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 16 Asia-Pacific Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 17 Asia-Pacific Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 18 Asia-Pacific Biologics Market, By Distribution Channel, 2020-2029 (USD Million)
TABLE 19 Asia-Pacific biologics market, By COUNTRY, 2020-2029 (USD MILLION)
TABLE 20 China Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 21 China Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 22 China B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 23 China Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 24 China Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 25 China Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 26 China Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 27 China Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 28 China Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 29 China Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 30 China Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 31 China Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 32 China Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 33 China Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 34 China Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 35 China Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 36 Japan Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 37 Japan Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 38 Japan B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 39 Japan Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 40 Japan Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 41 Japan Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 42 Japan Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 43 Japan Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 44 Japan Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 45 Japan Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 46 Japan Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 47 Japan Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 48 Japan Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 49 Japan Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 50 Japan Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 51 Japan Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 52 India Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 53 India Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 54 India B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 55 India Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 56 India Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 57 India Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 58 India Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 59 India Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 60 India Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 61 India Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 62 India Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 63 India Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 64 India Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 65 India Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 66 India Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 67 India Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 68 Australia Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 69 Australia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 70 Australia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 71 Australia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 72 Australia Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 73 Australia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 74 Australia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 75 Australia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 76 Australia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 77 Australia Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 78 Australia Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 79 Australia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 80 Australia Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 81 Australia Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 82 Australia Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 83 Australia Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 84 South Korea Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 85 South Korea Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 86 South Korea B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 87 South Korea Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 88 South Korea Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 89 South Korea Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 90 South Korea Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 91 South Korea Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 92 South Korea Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 93 South Korea Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 94 South Korea Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 95 South Korea Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 96 South Korea Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 97 South Korea Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 98 South Korea Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 99 South Korea Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 100 Singapore Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 101 Singapore Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 102 Singapore B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 103 Singapore Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 104 Singapore Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 105 Singapore Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 106 Singapore Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 107 Singapore Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 108 Singapore Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 109 Singapore Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 110 Singapore Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 111 Singapore Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 112 Singapore Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 113 Singapore Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 114 Singapore Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 115 Singapore Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 116 Malaysia Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 117 Malaysia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 118 Malaysia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 119 Malaysia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 120 Malaysia Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 121 Malaysia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 122 Malaysia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 123 Malaysia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 124 Malaysia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 125 Malaysia Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 126 Malaysia Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 127 Malaysia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 128 Malaysia Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 129 Malaysia Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 130 Malaysia Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 131 Malaysia Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 132 Indonesia Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 133 Indonesia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 134 Indonesia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 135 Indonesia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 136 Indonesia Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 137 Indonesia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 138 Indonesia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 139 Indonesia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 140 Indonesia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 141 Indonesia Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 142 Indonesia Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 143 Indonesia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 144 Indonesia Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 145 Indonesia Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 146 Indonesia Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 147 Indonesia Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 148 Thailand Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 149 Thailand Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 150 Thailand B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 151 Thailand Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 152 Thailand Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 153 Thailand Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 154 Thailand Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 155 Thailand Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 156 Thailand Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 157 Thailand Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 158 Thailand Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 159 Thailand Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 160 Thailand Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 161 Thailand Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 162 Thailand Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 163 Thailand Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 164 Philippines Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 165 Philippines Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 166 Philippines B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 167 Philippines Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 168 Philippines Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 169 Philippines Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 170 Philippines Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 171 Philippines Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 172 Philippines Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 173 Philippines Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 174 Philippines Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 175 Philippines Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 176 Philippines Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 177 Philippines Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 178 Philippines Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 179 Philippines Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 180 Vietnam Biologics Market, BY Class, 2020-2029 (USD Million)
TABLE 181 Vietnam Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 182 Vietnam B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 183 Vietnam Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)
TABLE 184 Vietnam Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 185 Vietnam Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 186 Vietnam Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 187 Vietnam Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)
TABLE 188 Vietnam Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)
TABLE 189 Vietnam Biologics Market, By Drug Classification, 2020-2029 (USD Million)
TABLE 190 Vietnam Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 191 Vietnam Oncology in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 192 Vietnam Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)
TABLE 193 Vietnam Biologics Market, By Source Material, 2020-2029 (USD Million)
TABLE 194 Vietnam Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 195 Vietnam Biologics Market, By End User, 2020-2029 (USD Million)
TABLE 196 Rest of Asia-Pacific Biologics Market, BY Class, 2020-2029 (USD Million)
List of Figure
FIGURE 1 Asia-Pacific biologics market: segmentation
FIGURE 2 Asia-Pacific biologics market: data triangulation
FIGURE 3 Asia-Pacific biologics market: DROC ANALYSIS
FIGURE 4 Asia-Pacific biologics market : REGIONAL vs country MARKET ANALYSIS
FIGURE 5 Asia-Pacific biologics market : COMPANY RESEARCH ANALYSIS
FIGURE 6 Asia-Pacific biologics market : multivariate modelling
FIGURE 7 Asia-Pacific biologics market: INTERVIEW DEMOGRAPHICS
FIGURE 8 Asia-Pacific biologics market: DBMR MARKET POSITION GRID
FIGURE 9 Asia-Pacific biologics market: vendor share analysis
FIGURE 10 Asia-Pacific biologics market: application type COVERAGE GRID
FIGURE 11 Asia-Pacific biologics market: SEGMENTATION
FIGURE 12 AN Increase in prevalEnce of chronic diseases such as diabetes and cancers and recent advancements in biologics are expected to drive THE Asia-Pacific biologics market IN THE FORECAST PERIOD of 2022 to 2029
FIGURE 13 tumor necrosis factor-A (TNF) Inhibitors segment is expected to account for the largest share of the Asia-Pacific biologics market in 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITES, AND CHALLENGE OF ASIA-PACIFIC BIOLOGICS MARKET
FIGURE 15 Asia-Pacific biologics market: BY class, 2021
FIGURE 16 ASIA-PACIFIC BIOLOGICS MARKET, BY class, 2020-2029 (USD MILLION)
FIGURE 17 ASIA-PACIFIC BIOLOGICS MARKET: BY class, CAGR (2022-2029)
FIGURE 18 ASIA-PACIFIC BIOLOGICS MARKET: BY class, LIFELINE CURVE
FIGURE 19 Asia-Pacific biologics market: BY route of administration, 2021
FIGURE 20 ASIA-PACIFIC BIOLOGICS MARKET, BY route of administration, 2020-2029 (USD MILLION)
FIGURE 21 ASIA-PACIFIC BIOLOGICS MARKET: BY route of administration, CAGR (2022-2029)
FIGURE 22 ASIA-PACIFIC BIOLOGICS MARKET: BY route of administration, LIFELINE CURVE
FIGURE 23 Asia-Pacific biologics market: BY drug classification, 2021
FIGURE 24 ASIA-PACIFIC BIOLOGICS MARKET, BY drug classification, 2020-2029 (USD MILLION)
FIGURE 25 ASIA-PACIFIC BIOLOGICS MARKET: BY drug classification, CAGR (2022-2029)
FIGURE 26 ASIA-PACIFIC BIOLOGICS MARKET: BY drug classification, LIFELINE CURVE
FIGURE 27 Asia-Pacific biologics market: BY source material, 2021
FIGURE 28 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, 2020-2029 (USD MILLION)
FIGURE 29 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, CAGR (2022-2029)
FIGURE 30 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC BIOLOGICS MARKET: By type, 2021
FIGURE 32 ASIA-PACIFIC BIOLOGICS MARKET: By type, 2020-2029 (USD MILLION)
FIGURE 33 ASIA-PACIFIC BIOLOGICS MARKET: By type, CAGR (2022-2029)
FIGURE 34 ASIA-PACIFIC BIOLOGICS MARKET: By type, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC BIOLOGICS MARKET: By application, 2021
FIGURE 36 ASIA-PACIFIC BIOLOGICS MARKET: By application, 2020-2029 (USD MILLION)
FIGURE 37 ASIA-PACIFIC BIOLOGICS MARKET: By application, CAGR (2022-2029)
FIGURE 38 ASIA-PACIFIC BIOLOGICS MARKET: By application, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC BIOLOGICS MARKET: By end user , 2021
FIGURE 40 ASIA-PACIFIC BIOLOGICS MARKET: By end USER, 2020-2029 (USD MILLION)
FIGURE 41 ASIA-PACIFIC BIOLOGICS MARKET: By end user , CAGR (2022-2029)
FIGURE 42 ASIA-PACIFIC BIOLOGICS MARKET: By end user , LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, 2021
FIGURE 44 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, 2020-2029 (USD MILLION)
FIGURE 45 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, CAGR (2022-2029)
FIGURE 46 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, LIFELINE CURVE
FIGURE 47 Asia-Pacific biologics market: SNAPSHOT (2021)
FIGURE 48 Asia-Pacific biologics market: BY COUNTRY (2021)
FIGURE 49 Asia-Pacific biologics market: BY COUNTRY (2022 & 2029)
FIGURE 50 Asia-Pacific biologics market: BY COUNTRY (2021 & 2029)
FIGURE 51 Asia-Pacific biologics market: BY CLASS (2022-2029)
FIGURE 52 ASIA-PACIFIC Biologics market: COMPANY SHARE 2021 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
